Moderate

Chronic myeloid leukaemia (CML) - management

CML · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A myeloproliferative neoplasm driven by the BCR::ABL1 fusion (Philadelphia chromosome). Tyrosine kinase inhibitors have transformed chronic-phase CML into a largely manageable condition with near-normal life expectancy and potential treatment-free remission.

Red flags

  • Rising blasts / transformation to accelerated or blast phase
  • Loss of molecular response or acquired T315I mutation
  • Marked leucocytosis with leukostasis symptoms
  • Severe TKI toxicity (pleural effusion, vascular events)
  • New extramedullary disease

Assessment

Differential diagnosis

  • Leukaemoid reaction
  • Other myeloproliferative neoplasms (PV, ET, MF)
  • Chronic myelomonocytic leukaemia
  • Atypical/BCR::ABL1-negative CML
  • Acute leukaemia (blast phase)

Investigations

  • FBC and film (leucocytosis with full myeloid spectrum, basophilia)
  • BCR::ABL1 by RT-PCR and cytogenetics for Philadelphia chromosome
  • Bone marrow aspirate/trephine for phase and additional abnormalities
  • Quantitative BCR::ABL1 (IS) for baseline and monitoring
  • Spleen assessment
  • Mutational analysis (e.g. T315I) if resistance

Management

  • Confirm diagnosis with BCR::ABL1 and define phase (chronic, accelerated, blast)
  • Calculate prognostic score (e.g. ELTS) and assess comorbidities for TKI selection
  • Start a tyrosine kinase inhibitor promptly in chronic phase (imatinib or a second-generation agent)
  • Select TKI considering risk, cardiovascular/metabolic profile and side-effect fit
  • Monitor response with quantitative BCR::ABL1 at defined milestones (3, 6, 12 months)
  • Aim for early molecular response and ongoing deep molecular response
  • Switch TKI for resistance or intolerance, guided by mutation analysis (ponatinib or asciminib for T315I)
  • Manage TKI side effects (cytopenias, fluid retention, vascular, QT, metabolic)
  • Consider treatment-free remission in patients with sustained deep molecular response
  • Reserve allogeneic transplant for advanced-phase or multi-TKI-resistant disease

Drugs & doses

Imatinib 400 mg PO once daily (chronic phase)
Dasatinib 100 mg PO once daily or nilotinib 300 mg PO twice daily (second generation)
Ponatinib 45 mg PO once daily or asciminib for T315I / resistant disease
Hydroxycarbamide PO for initial cytoreduction of high white count

Disposition

Haematology outpatient management; molecular monitoring; transplant referral for advanced disease.

Complications & pitfalls

  • Progression to blast crisis
  • TKI resistance (BCR::ABL1 mutations)
  • Cardiovascular/pleuropulmonary TKI toxicity
  • Cytopenias
  • Secondary malignancy (rare)

Exam pearls

  • Early molecular milestones predict long-term outcome - monitor BCR::ABL1 regularly
  • T315I confers resistance to most TKIs; ponatinib and asciminib retain activity
  • Sustained deep molecular response can allow carefully monitored treatment-free remission
  • Match TKI choice to the patient's cardiovascular and metabolic profile
  • Adherence strongly influences response - reinforce it

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.